Dr. Oscar Francesconi1,*, Prof. Cristina Nativi1, Dr. Gabriele Gabrielli1, Irene De Simone1, Sam Noppen2, Prof. Jan Balzarini2, Prof. Sandra Liekens2 andDr. Stefano Roelens3
Chemistry - A European Journal, Volume 21, Issue 28, pages 10089–10093, July 6, 2015
- DOI:
http://dx.doi.org/10.1002/chem.201501030
2 Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings.
Butt AA1,2,3, Yan P1, Shaikh OS1,2, Freiberg MS4, Lo Re V 3rd5, Justice AC6,7, Sherman KE8; ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Team
J Viral Hepat. 2015 Sep;22(9):691-700.
- DOI:
http://dx.doi.org/10.1111/jvh.12375
3 Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace.
De Clercq E1
Rev Med Virol. 2015 Jul;25(4):254-67
- DOI:
http://dx.doi.org/10.1002/rmv.1842
@}->--
